- Home
- TNXP vs RCS Comparison
TNXP vs RCS Comparison
Compare TNXP & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- RCS
- Stock Information
- Founded
- TNXP 2007
- RCS 1994
- Country
- TNXP United States
- RCS United States
- Employees
- TNXP N/A
- RCS N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- RCS Investment Managers
- Sector
- TNXP Health Care
- RCS Finance
- Exchange
- TNXP Nasdaq
- RCS Nasdaq
- Market Cap
- TNXP 335.6M
- RCS 334.5M
- IPO Year
- TNXP N/A
- RCS N/A
- Fundamental
- Price
- TNXP $28.35
- RCS $7.48
- Analyst Decision
- TNXP Buy
- RCS
- Analyst Count
- TNXP 1
- RCS 0
- Target Price
- TNXP $70.00
- RCS N/A
- AVG Volume (30 Days)
- TNXP 1.2M
- RCS 141.1K
- Earning Date
- TNXP 11-11-2025
- RCS 01-01-0001
- Dividend Yield
- TNXP N/A
- RCS 10.12%
- EPS Growth
- TNXP N/A
- RCS N/A
- EPS
- TNXP N/A
- RCS N/A
- Revenue
- TNXP $9,831,000.00
- RCS N/A
- Revenue This Year
- TNXP $14.79
- RCS N/A
- Revenue Next Year
- TNXP $933.49
- RCS N/A
- P/E Ratio
- TNXP N/A
- RCS N/A
- Revenue Growth
- TNXP N/A
- RCS N/A
- 52 Week Low
- TNXP $6.76
- RCS $4.51
- 52 Week High
- TNXP $130.00
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- TNXP 41.38
- RCS 73.92
- Support Level
- TNXP $26.89
- RCS $7.30
- Resistance Level
- TNXP $29.19
- RCS $7.49
- Average True Range (ATR)
- TNXP 2.18
- RCS 0.05
- MACD
- TNXP 0.39
- RCS 0.02
- Stochastic Oscillator
- TNXP 56.46
- RCS 97.64
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.